Journal of Clinical Oncology, Vol 15, 1143-1149, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL

KD Heckman, GJ Weiner, CS Davis, RG Strauss, MP Jones and CP Burns
Department of Medicine, The University of Iowa College of Medicine, Iowa City 52242, USA.

PURPOSE: We designed and conducted a randomized single-institution trial comparing two common prophylactic platelet transfusion thresholds in patients undergoing induction therapy for acute leukemia. PATIENTS AND METHODS: Seventy-eight patients undergoing induction therapy for acute leukemia were randomized to receive prophylactic apheresis platelet concentrates when the platelet count was either < or = 10,000/microL or < or = 20,000/microL. RESULTS: There was no significant difference in the total number of bleeding episodes per patient with a median of four in the < or = 10,000/microL arm and two in the < or = 20,000/microL arm (25th to 75th percentiles of 2, 7 and 1, 5, respectively; P = .12). Patients randomized to the < or = 10,000/microL arm received more platelet transfusions for bleeding [one (0, 2) v zero (0, 0); P = .0003]. In contrast, patients on the < or = 20,000/microL arm received more platelet transfusions for prophylactic indications [10 (5, 14) v six (3, 8); P = 0.001], as would be expected, but less for bleeding. Nevertheless, the total number of platelet transfusions given to patients on the < or = 20,000/microL arm was higher and nearly significant [11 (6, 15) v seven (5, 11); P = .07]. There were no statistically significant differences between the groups with regard to RBC transfusion requirements, febrile days, days hospitalized, days thrombocytopenic, need for HLA-matched platelets, remission rate, or death during induction chemotherapy. No patient in either group died from hemorrhage or underwent major surgery for bleeding complications. CONCLUSION: Giving prophylactic platelets at a threshold of < or = 10,000/microL compared with < or = 20,000/microL can decrease the total utilization of platelets with only a small adverse effect on bleeding, and no statistically significant effect on morbidity.

This article has been cited by other articles:

				H. Wandt, G. Ehninger, and W. M. Gallmeier New Strategies for Prophylactic Platelet Transfusion in Patients with Hematologic Diseases Oncologist, October 1, 2001; 6(5): 446 - 450. [Abstract] [Full Text] [PDF]

				C. A. Schiffer, K. C. Anderson, C. L. Bennett, S. Bernstein, L. S. Elting, M. Goldsmith, M. Goldstein, H. Hume, J. J. McCullough, R. E. McIntyre, et al. Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1519 - 1538. [Abstract] [Full Text] [PDF]

				L. S. Elting, E. B. Rubenstein, C. G. Martin, D. Kurtin, S. Rodriguez, E. Laiho, K. Kanesan, S. B. Cantor, and R. S. Benjamin Incidence, Cost, and Outcomes of Bleeding and Chemotherapy Dose Modification Among Solid Tumor Patients With Chemotherapy-Induced Thrombocytopenia J. Clin. Oncol., February 15, 2001; 19(4): 1137 - 1146. [Abstract] [Full Text] [PDF]

				S. C. Howard, A. Gajjar, R. C. Ribeiro, G. K. Rivera, J. E. Rubnitz, J. T. Sandlund, P. L. Harrison, A. de Armendi, G. V. Dahl, and C.-H. Pui Safety of Lumbar Puncture for Children With Acute Lymphoblastic Leukemia and Thrombocytopenia JAMA, November 1, 2000; 284(17): 2222 - 2224. [Abstract] [Full Text] [PDF]

				C. A. Schiffer, K. Miller, R. A. Larson, P. C. Amrein, J. H. Antin, V. J. Zani, and R. M. Stone A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia Blood, April 15, 2000; 95(8): 2530 - 2535. [Abstract] [Full Text] [PDF]

				M. Sagmeister, L. Oec, and J. Gmur A Restrictive Platelet Transfusion Policy Allowing Long-Term Support of Outpatients With Severe Aplastic Anemia Blood, May 1, 1999; 93(9): 3124 - 3126. [Abstract] [Full Text] [PDF]

				H. Wandt, M. Frank, G. Ehninger, C. Schneider, N. Brack, A. Daoud, I. Fackler-Schwalbe, J. Fischer, R. Gackle, T. Geer, et al. Safety and Cost Effectiveness of a 10 × 109/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 109/L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia Blood, May 15, 1998; 91(10): 3601 - 3606. [Abstract] [Full Text] [PDF]

				S. H. Bernstein, A. P. Nademanee, J. M. Vose, G. Tricot, J. W. Fay, R. S. Negrin, J. DiPersio, G. Rondon, R. Champlin, M. J. Barnett, et al. A Multicenter Study of Platelet Recovery and Utilization in Patients After Myeloablative Therapy and Hematopoietic Stem Cell Transplantation Blood, May 1, 1998; 91(9): 3509 - 3517. [Abstract] [Full Text] [PDF]

				P. Rebulla, G. Finazzi, F. Marangoni, G. Avvisati, L. Gugliotta, G. Tognoni, T. Barbui, F. Mandelli, G. Sirchia, and The Gruppo Italiano Malattie Ematologiche Maligne The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia N. Engl. J. Med., December 25, 1997; 337(26): 1870 - 1875. [Abstract] [Full Text] [PDF]